The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Maintenance therapy discontinuation in patients with deep measurable residual disease (MRD) negativity (<10⁻⁶ or <10⁻⁷) is associated with low rates of disease resurgence
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and 2024-2025 SOHO President Phillip Scheinberg, MD, PhD, of the Hospital Sao
CtDNA is a valuable biomarker for monitoring disease burden and predicting durable clinical benefit in second-line large B-cell lymphoma (LBCL) treatment, according to
Clearer standardized reporting of toxicity outcomes in phase 1 lymphoma trials is required for improved transparency and communication in drug development, according to
The ECOG-ACRIN MM20A-EA02 trial, part of the myeloMATCH precision medicine initiative from the US National Institutes of Health, is evaluating a novel combination
Patients with myelodysplastic syndromes (MDS) face varying progression risks based on clinical factors such as low hemoglobin levels and platelet counts, according to
Elranatamab in combination with carfilzomib and dexamethasone demonstrated clinical efficacy and predictable safety signals, according to the investigators of a phase 1b MagnetisMM-20
A review of patients treated with chimeric antigen receptor (CAR)-T cell therapy at a single institution revealed rare cases of second tumors, including
US military veterans with myeloproliferative neoplasms (MPNs) endure a substantial symptom burden and limited access to care, indicating suboptimal management, according to the
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel; Breyanzi) as a chimeric antigen receptor (CAR) T-cell
